Dianthus Therapeutics, Inc. $DNTH Stock Position Increased by Fisher Asset Management LLC

Key Points

• Fisher Asset Management increased its Dianthus stake by 1,068.4% in the third quarter, adding 249,510 shares to hold 272,863 shares, worth about $24 million. Institutional investors own 47.53% of the stock.
• Dianthus reported a quarterly loss of $0.81 per share, narrower than analysts’ $0.94 estimate, while revenue of $1.21 million exceeded the $0.46 million forecast. Analysts’ average rating is Buy, with an average price target of $128.77.
• Company insiders sold a combined 169,944 shares worth about $16 million over the past three months. EVP Ryan Savitz’s reported sale reduced his stake by 77.48%.

Fisher Asset Management LLC increased its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 1,068.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 272,863 shares of the company's stock after buying an additional 249,510 shares during the period. Fisher Asset Management LLC owned 0.50% of Dianthus Therapeutics worth $24,026,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of DNTH. BlackRock Inc. acquired a new position in Dianthus Therapeutics in the 2nd quarter valued at $401,990,000. Wellington Management Group LLP raised its holdings in Dianthus Therapeutics by 24.4% in the 2nd quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company's stock worth $314,849,000 after acquiring an additional 634,099 shares during the period. ABS Investment Management LLC acquired a new position in Dianthus Therapeutics during the 2nd quarter worth $194,960,000. Assenagon Asset Management S.A. lifted its position in Dianthus Therapeutics by 160.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 732,246 shares of the company's stock worth $64,474,000 after acquiring an additional 451,597 shares during the last quarter. Finally, Jennison Associates LLC bought a new stake in Dianthus Therapeutics during the first quarter valued at about $40,713,000. 47.53% of the stock is owned by institutional investors.

Recent Dianthus Therapeutics Headlines

Here are a few of the latest headlines about DNTH:

• Positive Sentiment: Analyst coverage is broadly favorable. A report highlights bullish views on DNTH, and HC Wainwright reiterated a Buy rating with a $158 price target and a bullish FY2026 earnings outlook. The available FY2026 report does not detail the estimate or its rationale. Article: Analysts Are Bullish on These Healthcare Stocks Article: HC Wainwright Has Bullish Estimate for DNTH FY2026 Earnings
• Negative Sentiment: EVP Ryan Savitz sold 124,042 shares from November 9–12 for about $11.2 million, sharply reducing his reported stake. The filings do not state why he sold, but the scale of the transactions may concern investors. Article: Dianthus Therapeutics EVP Sells Shares

Dianthus Therapeutics Stock Performance

Shares of NASDAQ:DNTH traded down $0.67 on Friday, hitting $91.81. 681,515 shares of the company were exchanged, compared to its average volume of 942,202. The company's 50 day moving average price is $88.45 and its two-hundred day moving average price is $86.56. Dianthus Therapeutics, Inc. has a one year low of $34.29 and a one year high of $117.88. The firm has a market capitalization of $5.17 billion, a price-to-earnings ratio of -23.01 and a beta of 1.47.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($0.94) by $0.13. Dianthus Therapeutics had a negative net margin of 7,436.50% and a negative return on equity of 19.68%. The business had revenue of $1.21 million during the quarter, compared to analyst estimates of $0.46 million. Research analysts predict that Dianthus Therapeutics, Inc. will post -3.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on DNTH shares. Truist Financial lifted their price objective on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Weiss Ratings restated a "sell (d-)" rating on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Roth Capital began coverage on Dianthus Therapeutics in a research note on Tuesday, October 27th. They set a "buy" rating and a $113.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and issued a $158.00 target price on shares of Dianthus Therapeutics in a report on Thursday, October 15th. Finally, Raymond James Financial reaffirmed a "strong-buy" rating and issued a $134.00 price target on shares of Dianthus Therapeutics in a research report on Thursday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Dianthus Therapeutics presently has an average rating of "Buy" and an average target price of $128.77.

Insider Transactions at Dianthus Therapeutics

In related news, EVP Ryan Savitz sold 100,713 shares of the business's stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $90.54, for a total transaction of $9,118,555.02. Following the transaction, the executive vice president directly owned 29,276 shares in the company, valued at $2,650,649.04. The trade was a 77.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Simrat Randhawa sold 23,124 shares of the company's stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $106.41, for a total value of $2,460,624.84. Following the completion of the transaction, the executive vice president directly owned 4,000 shares of the company's stock, valued at approximately $425,640. This trade represents a 85.25% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 169,944 shares of company stock valued at $16,043,319. 3.02% of the stock is currently owned by insiders.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company's research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.

Want to see what other hedge funds are holding DNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.